Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing, and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, today announced that a Phase I study of the best-in-class anti-CD24 antibody, ATG-031,…
Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC
Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that it will host a key opinion leader webcast on the current and future HCC (primary…
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
Virax Biolabs Group Limited (“Virax” or the “Company”) (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the appointment of Dr. Nigel McCracken as the Company’s Chief Operating Officer…
Sunrise Oncology Centre expands its horizon with a comprehensive cancer care unit in Mumbai
After setting up consecutive successful cancer care centers across Mumbai & Goa, Sunrise Oncology Centre inaugurates its latest comprehensive cancer care centre on 17th August 2023 in Andheri West, Mumbai. Founded in 2017 by the visionary trio Dr. Ashay Karpe,…
VENUS REMEDIES ONCOLOGY WING ON EXPANSION SPREE WITH MARKETING APPROVALS FROM FOUR KEY MARKETS
Making rapid strides in the oncology space by expanding its global reach, Venus Remedies Ltd, a well-known provider of affordable cancer drugs worldwide, has further consolidated its position in the Gulf Cooperation Council (GCC), Association of South East Asian Nations…
